How Effective Is PRP for Hip Osteoarthritis According to Clinical Studies?
Published November 16, 2026
Protocol: 7 steps in this guide
Hip-specific studies are mixed. A 2024 double-blind trial that compared PRP with saline injections in 60 people with hip osteoarthritis found no significant difference in pain, function or quality of life over six months. A 2026 meta-analysis comparing PRP with hyaluronic acid found a moderate advantage for PRP on pain but no difference in hip function, and that is a comparison between two active injections, not against a placebo. The 2026 U.S. Department of Veterans Affairs and Department of Defense guideline found the evidence insufficient to recommend for or against PRP in hip osteoarthritis. Knee results should not be assumed to apply to the hip.
Where intra-articular hip OA pain is felt
The hip joint lies deep, and pain around the hip can come from the joint or from structures outside it, such as the tendons on the outer side of the hip. Telling joint pain from those other sources is a clinical task, and the studies discussed here involve people diagnosed with hip osteoarthritis. A separate tendon problem at the outer hip is covered in PRP vs exercise therapy for gluteal tendinopathy.
Why deep-joint injection may require imaging
In the saline-controlled trial below, both groups received their injections into the hip joint under ultrasound guidance. Guidance is part of how hip injections were delivered in that study; the general role of imaging is covered in why some PRP injections are guided by ultrasound.
Hip-specific trial types and controls
The comparator decides what a hip result means. The two main sources answer different questions.
| Source | Design | Comparator | Result |
|---|---|---|---|
| Topaloglu and colleagues, Turkish Journal of Physical Medicine and Rehabilitation (2024) | Double-blind randomized trial; 60 patients with KL grade 2-3 hip OA (30 PRP, 30 saline); 3 weekly ultrasound-guided injections; 6-month follow-up | Saline placebo | No significant difference in pain, function or quality of life |
| Zhang and colleagues, Pain Research and Management (2026) | Meta-analysis; 7 studies, 465 patients | Hyaluronic acid | Better pain scores with PRP; no difference in hip function |
The saline-controlled trial is published as Effect of platelet-rich plasma injections versus placebo on pain and quality of life in patients with hip osteoarthritis. Its authors concluded that intra-articular PRP injections “show no significant difference compared to a saline placebo over a period of six months on pain, function, and quality of life scores.” Both groups improved in pain during activity at one and six months, which illustrates why a placebo group is needed before an improvement can be credited to PRP.
Pain, function and mobility are separate outcomes
The hyaluronic acid comparison shows why outcomes have to be read separately. The 2026 meta-analysis, Comparison of Clinical Efficiency and Safety Between Intra-Articular Injection of Platelet-Rich Plasma and Hyaluronic Acid for Hip Osteoarthritis, reported:
- Pain (VAS) at six months: better with PRP (SMD -0.38).
- WOMAC pain: better with PRP at six months (SMD -0.45) and twelve months (SMD -0.36).
- Hip function (Harris Hip Score and WOMAC function): no significant differences at any follow-up time.
- WOMAC total score: better with PRP (SMD -0.42).
The authors describe the pain advantage as having a moderate effect size and conclude that for joint function, measured by the Harris Hip Score and WOMAC function, “no significant differences were observed between the two groups.” In subgroup analyses, the six-month pain advantage was statistically significant for leukocyte-poor PRP and for multiple injections, but not for leukocyte-rich PRP or a single injection. Those formulation and dosing questions are covered in how leukocyte-rich and leukocyte-poor PRP differ and how many PRP injections are typically given in a treatment series.
A pain advantage over hyaluronic acid does not show that PRP beats a placebo; the only saline-controlled trial here found that it did not.
2026 VA/DoD interpretation
The VA/DoD Clinical Practice Guideline for the Non-Surgical Management of Hip & Knee Osteoarthritis (May 2026) states: “For osteoarthritis of the hip, there is insufficient evidence to recommend for or against platelet-rich plasma injections.” Its discussion cites a 2025 systematic review that found no difference in function on the Harris Hip Score or WOMAC between PRP and hyaluronic acid, or between PRP plus hyaluronic acid and hyaluronic acid alone, across six randomized trials, with one exception: short-term Harris Hip Score results favored PRP over hyaluronic acid. The guideline describes that review as limited by serious imprecision and methodological weaknesses.
“Insufficient evidence” is not proof that PRP fails; it means the guideline panel could not make a recommendation either way.
Exercise, mobility support and standard care
None of the hip studies above compares PRP with exercise or other standard non-injection care, and the VA/DoD guideline addresses other non-surgical treatments beyond injections. The place of PRP, if any, should be discussed with a clinician after standard options have been considered. None of the sources here shows that PRP delays the need for hip replacement.
What a useful hip trial should report
For a hip PRP study to be useful to patients, it should report:
- the severity of arthritis in the participants,
- the PRP preparation, including white cell content and platelet concentration,
- the number of injections and whether they were image-guided,
- a placebo or clearly defined active comparator,
- pain and function as separate outcomes, at more than one time point.
Knee evidence is reviewed separately in what the evidence says about PRP for knee osteoarthritis, and cell-based hip treatments in what evidence exists for cell-based treatments of hip osteoarthritis.
For hip osteoarthritis, PRP did not outperform saline in the one placebo-controlled trial reviewed here and showed only a moderate pain advantage over hyaluronic acid without better function, so it remains an unproven option that guidelines do not recommend for or against.
Cells linked to this one
This guide leads on to
- H3 PRP vs. Exercise Therapy for Gluteal Tendinopathy: What Does Research Show?
- B5 Why Are Some PRP Injections Guided by Ultrasound?
- B2 What Is the Difference Between Leukocyte-Rich and Leukocyte-Poor PRP?
- B6 How Many PRP Injections Are Typically Given in a Treatment Series?
- C1 What Does the Evidence Say About PRP for Knee Osteoarthritis?
- F2 What Evidence Exists for Cell-Based Treatments of Hip Osteoarthritis?
Add a remark